Henry Dorkin

Henry Dorkin, MD

Associate Chief, Division of Respiratory Diseases; Co-Director, Cystic Fibrosis Center

Associate Professor of Pediatrics, Harvard Medical School

  • Contact: 617-355-1900

  • Fax: 617-730-0373

Medical Services

Specialties

  • Cough
  • Cystic Fibrosis
  • Chronic Lung Disease
  • Pneumonia
  • Pulmonary Medicine
  • Respiratory Disease

Departments

  • Pulmonary and Respiratory Diseases

Programs

  • General Pulmonary Program
  • Cystic Fibrosis Center
To schedule an appointment: Call 617-355-1900 or Request an Appointment

Experience and Education

Education

Johns Hopkins University,

Johns Hopkins University (Pediatrics),

Johns Hopkins University,

Children's Hospital Boston (Pulmonary),

Certifications

  • Pediatric Pulmonology

Publications

Publications powered by Harvard Catalyst
  1. Dorkin HL, Staab D, Operschall E, Alder J, Criollo M. Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis. BMJ Open Respir Res. 2015; 2(1):e000100.
  2. Gaggar A, Chen J, Chmiel JF, Dorkin HL, Flume PA, Griffin R, Nichols D, Donaldson SH. Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis. J Cyst Fibros. 2016 Mar; 15(2):227-33.
  3. Lee EY, Dorkin H, Vargas SO. Congenital pulmonary malformations in pediatric patients: review and update on etiology, classification, and imaging findings. Radiol Clin North Am. 2011 Sep; 49(5):921-48.
  4. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, De Boeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, Ordoñez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012 Jan; 67(1):12-8.
  5. Hale JE, Parad RB, Dorkin HL, Gerstle R, Lapey A, O'Sullivan BP, Spencer T, Yee W, Comeau AM. Cystic fibrosis newborn screening: using experience to optimize the screening algorithm. J Inherit Metab Dis. 2010 Oct; 33(Suppl 2):S255-61.
  6. Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP, Spencer LT, Pilewski J, Waltz DA, Dorkin HL, Ferkol T, Pian M, Ramsey B, Carter BJ, Martin DB, Heald AE. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther. 2007 Aug; 18(8):726-32.
  7. O'Sullivan BP, Zwerdling RG, Dorkin HL, Comeau AM, Parad R. Early pulmonary manifestation of cystic fibrosis in children with the DeltaF508/R117H-7T genotype. Pediatrics. 2006 Sep; 118(3):1260-5.
  8. Shnayderman M, Mansfield B, Yip P, Clark HA, Krebs MD, Cohen SJ, Zeskind JE, Ryan ET, Dorkin HL, Callahan MV, Stair TO, Gelfand JA, Gill CJ, Hitt B, Davis CE. Species-specific bacteria identification using differential mobility spectrometry and bioinformatics pattern recognition. Anal Chem. 2005 Sep 15; 77(18):5930-7.
  9. Parad RB, Comeau AM, Dorkin HL, Dovey M, Gerstle R, Martin T, O'Sullivan BP. Sweat testing infants detected by cystic fibrosis newborn screening. J Pediatr. 2005 Sep; 147(3 Suppl):S69-72.
  10. Comeau AM, Parad R, Gerstle R, O'Sullivan BP, Dorkin HL, Dovey M, Haver K, Martin T, Eaton RB. Challenges in implementing a successful newborn cystic fibrosis screening program. J Pediatr. 2005 Sep; 147(3 Suppl):S89-93.
  11. Show all
  12. Comeau AM, Parad R, Gerstle R, O'Sullivan BP, Dorkin HL, Dovey M, Haver K, Martin T, Eaton RB. Communications systems and their models: Massachusetts parent compliance with recommended specialty care after positive cystic fibrosis newborn screening result. J Pediatr. 2005 Sep; 147(3 Suppl):S98-100.
  13. Comeau AM, Parad RB, Dorkin HL, Dovey M, Gerstle R, Haver K, Lapey A, O'Sullivan BP, Waltz DA, Zwerdling RG, Eaton RB. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics. 2004 Jun; 113(6):1573-81.
  14. Wheeler PG, Smith R, Dorkin H, Parad RB, Comeau AM, Bianchi DW. Genetic counseling after implementation of statewide cystic fibrosis newborn screening: Two years' experience in one medical center. Genet Med. 2001 Nov-Dec; 3(6):411-5.
  15. Joseph PM, O'Sullivan BP, Lapey A, Dorkin H, Oren J, Balfour R, Perricone MA, Rosenberg M, Wadsworth SC, Smith AE, St George JA, Meeker DP. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. Hum Gene Ther. 2001 Jul 20; 12(11):1369-82.
  16. Perricone MA, Morris JE, Pavelka K, Plog MS, O'Sullivan BP, Joseph PM, Dorkin H, Lapey A, Balfour R, Meeker DP, Smith AE, Wadsworth SC, St George JA. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium. Hum Gene Ther. 2001 Jul 20; 12(11):1383-94.
  17. Redding GJ, Cloutier MM, Dorkin HL, Brotherton SE, Mulvey HJ. Practice of pediatric pulmonology: results of the Future of Pediatric Education Project (FOPE) Pediatr Pulmonol. 2000 Sep; 30(3):190-7.
  18. Meissner HC, Welliver RC, Chartrand SA, Law BJ, Weisman LE, Dorkin HL, Rodriguez WJ. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J. 1999 Mar; 18(3):223-31.
  19. Eisenberg JD, Aitken ML, Dorkin HL, Harwood IR, Ramsey BW, Schidlow DV, Wilmott RW, Wohl ME, Fuchs HJ, Christiansen DH, Smith AL. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J Pediatr. 1997 Jul; 131(1 Pt 1):118-24.
  20. Jackson AC, Neff KM, Dorkin HL, Lutchen KR. Interpretation of respiratory input impedance in healthy infants. Pediatr Pulmonol. 1996 Dec; 22(6):364-75.
  21. Stone PJ, Konstan MW, Berger M, Dorkin HL, Franzblau C, Snider GL. Elastin and collagen degradation products in urine of patients with cystic fibrosis. Am J Respir Crit Care Med. 1995 Jul; 152(1):157-62.
  22. Grubman SA, Fang SL, Mulberg AE, Perrone RD, Rogers LC, Lee DW, Armentano D, Murray SL, Dorkin HL, Cheng SH, et al. Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary epithelial cell lines. Gastroenterology. 1995 Feb; 108(2):584-92.
  23. Ramsey BW, Dorkin HL. Consensus conference: practical applications of Pulmozyme. September 22, 1993. Pediatr Pulmonol. 1994 Jun; 17(6):404-8.
  24. Ramsey BW, Astley SJ, Aitken ML, Burke W, Colin AA, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Schidlow DV, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis. 1993 Jul; 148(1):145-51.
  25. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, Schidlow DV, Wilmott RW, Astley SJ, McBurnie MA, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med. 1993 Jun 17; 328(24):1740-6.
  26. Richards B, Skoletsky J, Shuber AP, Balfour R, Stern RC, Dorkin HL, Parad RB, Witt D, Klinger KW. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet. 1993 Feb; 2(2):159-63.
  27. Jefferson DM, Valentich JD, Marini FC, Grubman SA, Iannuzzi MC, Dorkin HL, Li M, Klinger KW, Welsh MJ. Expression of normal and cystic fibrosis phenotypes by continuous airway epithelial cell lines. Am J Physiol. 1990 Dec; 259(6 Pt 1):L496-505.
  28. Lutchen KR, Habib RH, Dorkin HL, Wall MA. Respiratory impedance and multibreath N2 washout in healthy, asthmatic, and cystic fibrosis subjects. J Appl Physiol (1985). 1990 May; 68(5):2139-49.
  29. Jackson AC, Giurdanella CA, Dorkin HL. Density dependence of respiratory system impedances between 5 and 320 Hz in humans. J Appl Physiol (1985). 1989 Dec; 67(6):2323-30.
  30. Dorkin HL, Lutchen KR, Jackson AC. Human respiratory input impedance from 4 to 200 Hz: physiological and modeling considerations. J Appl Physiol (1985). 1988 Feb; 64(2):823-31.
  31. Jackson AC, Lutchen KR, Dorkin HL. Inverse modeling of dog airway and respiratory system impedances. J Appl Physiol (1985). 1987 Jun; 62(6):2273-82.
  32. Miller K, Gouveia WA, Barza M, Bower K, Curtis L, Decker EL, Dorkin H, Estes M, Mackey W, Marchbein D, et al. Undesirable marketing practices in the pharmaceutical industry. N Engl J Med. 1985 Jul 4; 313(1):54.
  33. Dorkin HL, Stark AR, Werthammer JW, Strieder DJ, Fredberg JJ, Frantz ID. Respiratory system impedance from 4 to 40 Hz in paralyzed intubated infants with respiratory disease. J Clin Invest. 1983 Sep; 72(3):903-10.
  34. Schwartz AM, Dorkin HL, Carter BL. CT appearance of the liver in a patient with biliary cirrhosis and cystic fibrosis. J Comput Assist Tomogr. 1983 Jun; 7(3):530-3.
  35. Dorkin HL, Jackson AC, Strieder DJ, Dawson SV. Interaction of oscillatory and unidirectional flows in straight tubes and an airway cast. J Appl Physiol Respir Environ Exerc Physiol. 1982 Apr; 52(4):1097-1105.
  36. Fredberg JJ, Wohl ME, Glass GM, Dorkin HL. Airway area by acoustic reflections measured at the mouth. J Appl Physiol Respir Environ Exerc Physiol. 1980 May; 48(5):749-58.
  37. Caplan LM, Dobson ML, Dorkin H. Yersinia enterocolitica septicemia. Am J Clin Pathol. 1978 Feb; 69(2):189-92.
  38. Siggers DC, Rogers JG, Boyer SH, Margolet L, Dorkin H, Banerjee SP, Shooter EM. Increased nerve-growth-factor beta-chain cross-reacting material in familial dysautonomia. N Engl J Med. 1976 Sep 16; 295(12):629-34.
  39. Fisher RA, Turner BM, Dorkin H, Harris H. An investigation of some factors affecting levels of erythrocyte inorganic pyrophosphatase activity. Clin Chim Acta. 1975 May 15; 61(1):27-37.
  40. Fisher RA, Turner BM, Dorkin HL, Harris H. Studies on human erythrocyte inorganic pyrophosphatase. Ann Hum Genet. 1974 Jan; 37(3):341-53.
To schedule an appointment: Call 617-355-1900 or Request an Appointment

Locations

We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close